Table 1.
In the study of Goldberg et al a total of 802 subjects were randomized to blinded treatment with maximal dose of either pioglitazone or rosiglitazone to determine the effect of these agents on fasting lipids in the setting of no other glucose or lipid-lowering therapy. The observed changes in lipid concentrations from baseline are shown73
| Outcome measure | Pioglitazone (n = 363) | Rosiglitazone (n = 356) |
|---|---|---|
| Triglycerides, mmol/L | −0.59 ± 0.09 | 0.15 ± 0.09 |
| HDL-C, mmol/L | 0.13 ± 0.01 | 0.06 ± 0.01 |
| Non-HDL, mmol/L | 0.09 ± 0.05 | 0.67 ± 0.05 |
| LDL, mmol/L | 0.32 ± 0.04 | 0.55 ± 0.04 |
| TC, mmol/L | 0.23 ± 0.05 | 0.73 ± 0.05 |
| TC-to-HDL ratio | −0.3 ± 0.1 | 0.7 ± 0.1 |
| Apolipoprotein B, g/L | 0.00 ± 0.01 | 0.11 ± 0.01 |
Notes: Data are means ± SE; p < 0.001 for all outcomes measures listed here.
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.